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The first episode psychosis is a variable syndrome defined by the presence of positive 
and negative symptoms with a continuous duration of at least one week. Typically it 
begins in adolescence or young adulthood. The prevalence of tobacco use in patients with 
first episode psychosis is markedly high, about 59%, higher than in the general 
population. Most of the existing studies currently refer to patients with chronic psychotic 
disorders. Thus, there has been crescent interest in understanding the concrete origin of 
the relationship between tobacco and the first psychotic episode. This systematic review 
reunites the studies published until March 2018, through a search in Pubmed and Web of 
Knowledge databases, in order to study three main aims that could contribute to the 
existence of the relationship between tobacco and first psychotic episode: 1)Tobacco 
smoking as a potential risk factor to first episode psychosis; 2)Nicotine use in the form of 
tobacco smoking in first episode psychosis: the self-medication hypothesis; and 
3)Tobacco use as a marker of greater illness severity in first episode psychosis. Ten 
original articles were included, of which: one studied the first topic mentioned above; 
four studied the second; and the remaining five studied the third hypothesis. This review 
concludes that the relationship between tobacco and the first psychotic episode is 
undeniable, and, in spite of being difficult to reach the nature of this association, there 
was a trend towards a greater contribution of the hypothesis “Tobacco smoking as a 
potential risk factor to first episode psychosis” comparative to the “Nicotine use in the 
form of tobacco smoking in first episode psychosis: the self-medication hypotheses”. The 
last hypothesis "Tobacco as a marker of disease severity" was the one that was most 
corroborated, with four of the five studies included in this topic supporting this 
hypothesis. In one study, it is suggested that poor adherence to medication may be a causal 
factor that mediates the association between smoking and increased severity of the 
disease. It was found that, although further studies on this associations are necessary, if 
fully tested, it may be very useful in clinical practice, primarily in a view of prevention 
and also in the staging of the disease. 
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O primeiro episódio psicótico é uma síndrome variável que se define pela presença de 
sintomas positivos e negativos com uma duração contínua mínima de uma semana. 
Tipicamente tem início na adolescência e idade adulta jovem. A prevalência do uso de 
tabaco em doentes com primeiro episódio psicótico é marcadamente elevada, cerca de 
59%, superior comparativamente à da população em geral. A maioria dos estudos 
existentes atualmente refere-se a doentes com doença psicótica crónica. Desta forma, 
tem-se manifestado interesse em entender a origem concreta da relação entre o tabaco e 
o primeiro episódio psicótico. Esta revisão sistemática reuniu os estudos publicados até 
março de 2018, através da pesquisa nas bases de dados Pubmed e Web of Knowledge, 
sobre a relação referida de forma a estudar três tópicos principais que poderão contribuir 
para a associação entre o tabaco e o primeiro episódio psicótico: 1)Tabaco como fator de 
risco do primeiro episódio psicótico; 2)A exposição à nicotina, através do tabaco, como 
comportamento de auto-medicação, e 3)Tabaco como marcador de gravidade da doença. 
Foram incluídos dez artigos originais, dos quais: um estudou o primeiro tópico acima 
referido; quatro estudaram o segundo; e os restantes cinco estudaram a terceira hipótese. 
Esta revisão permite concluir que a relação entre o tabaco e o primeiro episódio psicótico 
é inegável, e, apesar de ser dificil de alcançar a verdadeira génese da mesma, houve uma 
tendência para mostrar uma maior contribuição da hipótese “Tabaco como fator de risco 
do primeiro episódio psicótico” em relação à hipótese “A exposição à nicotina, através 
do tabaco, como comportamento de auto-medicação”. A última hipótese “Tabaco como 
marcador de gravidade da doença” foi aquela que mais foi corroborada, com quatro dos 
cinco estudos incluídos neste tópico a apoiar esta hipótese. Num dos estudos, sugere-se 
que a fraca adesão à medicação possa ser um fator causal que medeia a associação entre 
o tabaco e uma maior severidade da doença. Constatou-se, desta forma, que, apesar de 
serem necessários mais estudos sobre estas associações, no caso de serem totalmente 
provadas, poderão ter uma utilidade clínica muito vantajosa, primeiramente, numa 
perspetiva de prevenção e ainda no estadiamento da doença. 
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The first episode psychosis (FEP) is defined as a variable syndrome, lasting continuously 
for at least one week, characterized by the presence of positive symptoms, predominantly 
hallucinations and delusional ideas, and other accompanying symptoms, including 
negative, affective and cognitive symptoms. Typically, its begin during adolescence and 
young adulthood (1). 
The prevalence of tobacco use in first episode psychosis patients is markedly high, about 
59%, higher than in the general population (2). 
In a study of a population of the United States of America, against age and sex, was 
observed a 12-month mortality among young people after a diagnosis of first episode 
psychosis at least 24 times greater than the general population (3). Also, it is suggested 
that cardiovascular mortality in schizophrenia has been increasing relative to the general 
population, a large part of the excess mortality probably attributed to the effects of 
smoking. (4)  
On the other hand, the fact that tobacco dependence is a high financial burden also 
contributes to the social disadvantage and consequent decline of many of these patients. 
(5) 
Several theories have been proposed to explain the reason why individuals with psychosis 
are more vulnerable to initiate and maintain tobacco use. 
A causal role of tobacco in the first episode psychosis has been suggested, taking into 
account the interpretation of results as the association between tobacco use and an 
increased risk of psychosis, despite the awareness that this effect may be modest. (6)  
In fact, there is some biological plausibility in this association. Tobacco contains almost 
5,000 different chemicals, with nicotine being the most important pharmacologically 
active and psychogenic component because of its interaction with nicotinic acetylcholine 
receptors (nAChRs) (7), which exhibit distinct patterns of expression that are in parallel 
with major developmental events within the cholinergic system which are in turn critical 
regulators of brain maturation from prenatal development to adolescence. (8)  
Several studies on smoking suggest that nicotine may alter the signaling of dopaminergic, 
cholinergic and glutamatergic neurotransmitter systems (9, 10) and thus may influence 
brain development, as suggested by studies on nicotine exposure in adolescents (9). 
Excessive exposure to nicotine during early adolescence is associated with abnormal 
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maturation of the white matter in adults (11) and chronic smoking has been associated 
with structural brain changes, such as decreased gray matter in the prefrontal cortex, 
which correspond to areas where functional changes occur due to exposure to nicotine 
(12).  
Early intervention in psychosis was the one that showed the greatest progress on the 
classical pessimism associated with the disease, possible through the identification of the 
patients with ultra-high risk of psychosis and consequent possibility of intervening 
therapeutically at an earlier stage (13). Also, giving to the first episode psychosis patients 
the evidence based interventions effective in this phase of the disorder. It becomes more 
and more important to identify possible risk factors for the development of the disease in 
order to prevent or reduce exposure to them. 
 
In another point of view, the question has been raised if the widespread smoking behavior 
that is seen in this patient group is in fact a relation of cause-effect or it is instead a 
manifestation of a common underlying physiology, being tobacco an attempt to self-
medication. 
There are different types of nicotinic receptors once multiple subtypes of pentameric 
structures with unique combinations form at least twelve (α2–α10, β2–β4) genetically-
distinct subunits (14). The existence of these different types of nAChRs leads to the 
consequence that different doses of nicotine will promote different pharmacological 
effects (15). Since inhalation of cigarette smoke results in almost immediate absorption 
of nicotine, it might be possible for a smoker to control their nicotine dose to achieve the 
desired effect(s) (15). 
Nicotinic acetylcholine receptors appear to be associated with different functional 
systems, by modulating the effects of different transmitter pathways, including the 
cholinergic system itself (by both pre- and post-synaptic mechanisms), and the dopamine 
(DA), glutamate, GABA, 5-HT, norepinephrine, opioid, and histaminergic systems (16). 
In the case of dopamine system, the pleasurable and reinforcing effects of nicotine are 
believed to arise via an interaction of the drug with the mesocorticolimbic system (15), 
once nicotine elicits dopamine release in the Ventral Tegmental Area (VTA), which 
projects to many brain regions like prefrontal cortex (PFC), dorsal striatum, nucleus 
accumbens (NAc), ventral pallidum (VP), hippocampus and amygdala (17) and which is 
known to play an important role in drug addiction (14). 
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It has been described a possible therapeutic role of nicotine for negative symptoms in 
psychosis. This effect is thought to be due to a raise in the dopamine levels in the nucleus 
accumbens and prefrontal cortex (18).  
In fact, according to the dopaminergic theory, the negative symptoms present in this 
disorder are caused by hypoactivation of the dopaminergic mesocortical projections, 
which results in a hypostimulation of the D1 receptors. Also corroborating this 
hypothesis, atypical antipsychotics, which have shown the potential to decrease negative 
symptoms, are thought to do so by serotonergic antagonistic activity (5-HT) since, by 
blocking these receptors, there is an increase in the release of dopamine in the 
mesocortical pathway (1). 
In this way, it calls attention for a possible common underlying physiology between 
nicotine and atypical antipsychotics. 
 
Still on this subject, typical antipsychotics, through blocking the D2 receptors in the 
mesolimbic dopaminergic pathway, reduces the positive symptoms, such as 
hallucinations; however, the blockade is not limited to the mesolimbic pathway, 
simultaneously blocking other dopaminergic pathways, which aggravates negative 
symptoms and promotes the onset of extrapyramidal effects by blocking D2 receptors in 
the nigrostriatal dopaminergic pathway (1). Giving raise to the self-medication theory, 
reports showed reduced rates of smoking in patients treated with atypical antipsychotics 
compared to those treated with typical antipsychotics (19). 
 
It was still suggested that tobacco use could serve as a marker of severity in psychotic 
illness (20), as it has been associated with an increase in negative (21, 22) and positive 
(23) symptoms, as well as poorer global functioning (24) and also social adjustment (25). 
However, it may not be representative of first episode psychotic individuals once those 
clinical outcomes are from patients who have a chronic disease. 
 
This systematic review reunites the current evidence of three main aims: 1. Tobacco 
smoking as a potential risk factor to first episode psychosis; 2. Nicotine use in the form 
of tobacco smoking in first episode psychosis: the self-medication hypothesis; 3. Tobacco 
use as a marker of greater illness severity in first episode psychosis. The major objective 




Pubmed and Web of Knowledge databases were searched for published articles using 
keywords “tobacco” OR “tobacco use” OR “tobacco smoking” AND “first episode 
psychosis” OR “first episode schizophrenia”. In addition, a secondary search was 
performed by reviewing reference lists of sources identified as relevant in initial search 
to find more articles to this review. The articles were included if they were original 
articles and written in English. This systematic review included articles until March 2018. 
Studies were excluded if were related to chronic schizophrenia patients or psychiatric 
populations other than first-episode psychosis. In case of multiple publications deriving 
from the same study population, we selected the articles reporting the largest or the most 







Ten articles were included in the systematic review. 
One article was included that studied tobacco as a potential risk factor to first episode 
psychosis (26), four articles that examined the self-medication hypothesis (27-30) and 
five articles that studied tobacco use as a marker of greater illness severity in first episode 
psychosis (31-35). 
A total of 2567 patients were included, sample size ranged from 41 to 503 patients, with 
mean age from 20,5 to 29,9 years, with male percentage from 28,1 to 72,5 %. Two studies 
are from Canada, four are from Spain, one is from UK, one study is from Australia, one 
study is from USA and one study is from Poland. Three studies were published between 
2008 and 2012 and seven between 2015 and 2018 (inclusive).   
3.1. Prevalence of smoking 
 
The prevalence of smoking in first episode psychosis patients ranged from 36,7% to 72,0 
%. In one article it was not possible to determine the prevalence of smoking (26). 
There was no significant gender difference on tobacco use in first episode psychosis 
patients in most studies, with the exception of three studies: one study in which when the 
FEP group was stratified by smoking status, significant differences emerged in gender, 
with 65% of males smokers versus 47% of female smokers (29); other second study, in 
which the male smoker percentage was 64,8% against the male general percentage of 
56,9% (30); and a third study, in which statistically significant associations were found 
between smoking status and gender, with male subjects more than three times as likely to 
smoke as females (35). 
In one study, when the FEP group was stratified by smoking status, significant differences 
emerged in age, with a mean age of 28,1 in smokers and 32,3 in non-smokers (29). In a 
second study, also smokers showed a mean age of 28,2, while non-smokers showed a 
mean age of 32,2 (30). Lastly, heavy smokers were older than light/moderate smokers 







3.2. Tobacco smoking as a potential risk factor to first episode psychosis  
 
In 2009, a study showed that the mean age at starting smoking was earlier than the onset 
of psychosis, which can be suggestive of a causal role of the tobacco in the onset of 
psychosis (26). Besides this, the proportion of patients who started smoking by the onset 
of a functional decline was significantly high comparative to the general population. In 
more detail, the percentage of patients who smoked for patients aged 20 years or more 
was 70% and lower for teenager patients (49%), which also suggests that some patients 
initiate smoking after their first referral for treatment. In addiction and also supporting 
the idea of tobacco smoking as a risk factor for psychosis, smoker patients showed a 
nonsignificant better functioning compared to nonsmoker patients and also those patients 
who started smoking had better premorbid social functioning than those who did not 
smoke, which is contrary to what was expected in case smoking were initiated in response 
to early prodromal features of illness. 
 
3.3. Nicotine use in the form of tobacco smoking in first episode psychosis: the 
self-medication hypothesis 
The four articles included in this systematic review were divergent with a general 
conclusion that goes against the self-medication hypothesis. 
Recently, in 2018, a study (27) tested the following hypothesis: tobacco using FEP 
patients have better non-social and social cognitive performance than non-tobacco using 
FEP patients; tobacco smoker patient group presented worse non-social and social 
cognitive performance than the tobacco-smoker and non-smoker control group. The 
results showed no differences between the patient groups (tobacco users and non-tobacco 
users). Taking into account these results, this study suggests that tobacco use in FEP 
patients is not related to better non-social or social cognitive performance, which do not 
support the self-medication hypothesis. Despite this, it’s important to be aware of a 
limitation of this study, which is the lack of IQ matching between patients and healthy 
controls, specifically, the control group had a significantly higher IQ compared to the 
patient group and this difference remained significant when the sample was subdivided 




Misiak et al. investigated the relationship between nicotine dependence and 
psychopathology in FEP patients, in particular, and with more interest for this review, it 
was studied the association between the severity of nicotine dependence and scores of 
negative and positive symptoms. It was found that cigarette smoking is associated with 
lower severity of negative symptoms, although this difference is significant only in the 
comparison of severe nicotine dependence patients and non-smokers (28), indicating that 
cigarette smoking might be enrolled in the psychopathology of this illness, by inducing 
less severe negative symptoms. 
 
Hickling et al. analyzed the relationship between chronic exposure to nicotine through 
tobacco smoking on cognitive performance and there was no significant difference in any 
of the cognitive areas between smokers and non-smokers in the FEP group and also in 
the healthy group (29).  
 
Still within this topic, Hickling et al. published a study which focused on the effects of 
tobacco smoking on age of onset of psychosis and psychotic symptoms in a first-episode 
psychosis population. The study conclusion was that tobacco smoking had no effect on 
psychopathology at initial presentation or treatment response at 6 weeks (30). 
 
3.4. Tobacco use as a marker of greater illness severity in first episode psychosis 
Four of the five studies included in this topic supported this hypothesis. 
An observational study (31) was conducted to determine if there is cognitive benefit 
achieved via smoking by comparing the cognitive performance of smoking and non-
smoking FEP patients. In their baseline report, it was found that smoking FEP patients 
performed better in tasks measuring attention and working memory than non-smoking 
patients after stabilization (36). In the present longitudinal report, these patients were 
followed up in order to determine possible differences in attention and working memory 
between smoking and non-smoking patients 1 year after the initiation of antipsychotic 
treatment and the secondary objective was to explore the relationship between smoking 
and the symptoms and side effects of antipsychotics. It was observed that, after 6 months 
the initiation of antipsychotic treatment, baseline differences in selective attention and 
working memory parameters were no longer significant between smokers and non-
smokers, with the exception of Stroop-I mean RT (Stroop Color-Word Test Interference 
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score/Stroop-I, the measure of selective attention) and after 1 year, performance was 
similar between the groups. Another point that deserves attention is that smokers did not 
show any cognitive response to SGA, with no synergic effects observed for nicotine and 
antipsychotics. In addition, although the results of this study indicate that the initial 
clinical presentation is the same between groups, it was found that negative symptoms 
worsen significantly in smokers. With respect to the exploration of the association 
between smoking and symptoms and side effects of medication, this study results do not 
support that FEP patients smoke in order to reduce the side effects of antipsychotic drugs, 
once smokers did not show fewer extrapyramidal side effects comparative to non-
smokers (31). 
In another study it was found that cigarette smoking was consistently associated with 
higher ratings of psychiatric symptoms and functional impairment, more missed pills and 
lower ratings of quality of life (32). This study results encourage the hypothesis of tobacco 
being a marker of greater illness severity. 
In a one year follow-up study of first episode psychosis (33), the following hypotheses 
were addressed: firstly, if substance use (including tobacco) following illness onset 
impairs medication adherence; secondly, if substance use is associated with poor outcome 
at 1 year follow-up, and finally if the poor medication adherence mediates this effect. The 
results indicate that in fact nicotine dependence in the first year after psychosis onset 
affect medication adherence. Furthermore, poor medication adherence predicts non-
remission and lastly nicotine dependence in the first year after psychosis onset are 
associated with increased probability of non-remission during the one year follow-up and 
medication adherence is involved in it by mediating these effects.  
A recent study demonstrated that neurocognitive and functional impairments are more 
prominent in light/moderate and heavy cigarette smokers with FEP relative to non-
smoking patients at initial presentation for treatment (34), which reinforces the theory 
that cigarette smoking may be indicative of a greater illness severity. 
In a 7.5-year follow-up study of a first episode psychosis cohort, the conclusion was that 
there were not any impact of smoking on clinical outcomes in individuals after a first 
episode psychosis (35), disapproving the primary hypothesis of the study which was that 
smoking would be associated with poorer clinical and functional outcomes and also 
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contrasting with the previous conclusions in this review that connected smoking with a 












Diagnosis Main Aim Prevalence Relevant findings 
Risk factor 
(26) 
Canada 115 20,5 
(5,5) 




Determine the predictors of 
starting to smoke in patients 
with first episode psychosis. 
 The mean age at starting 
smoking was earlier than the 
onset of psychosis, which can 
be suggestive of a causal role of 










Test if tobacco using FEP 
patients have better non-
social and social cognitive 
performance than non-
tobacco using FEP patients. 
67,8% No differences were revealed in 
the comparison between the 
patient groups (tobacco users 
and non-tobacco users), 
suggesting that tobacco in FEP 
patients is not related to better 
non-social or social cognitive 
performance. 
(28) Poland 109 27,7 56,0% First-episode 
schizophrenia 
Investigate the relationship 
between nicotine 
dependence and 
psychopathology in FEP 
patients. 
36,7% Cigarette smoking is associated 








Analyze the relationship 
between chronic exposure to 
nicotine on cognitive 
performance. 
57% No difference in cognitive 
ability was found between 
smokers and non-smokers. 




Analyze the effects of 
tobacco smoking on age of 
onset of psychosis and 
psychotic symptoms in a 
FEP population. 
58,7% Smoking had no effect on 
psychopathology at initial 
presentation or treatment 
response at 6 weeks. 
Greater illness 
severity 
        




Determine if there is 
cognitive benefit achieved 
via smoking by comparing 
the cognitive performance 
of smoking and non-
smoking FEP patients and 
explore the relationship 
between smoking and the 
symptoms and side effects 
of antipsychotics. 
63,4% Smoking patients lost their 
superior baseline performance, 
did not obtain any cognitive 
benefit after treatment and 
worsen their symptoms. Also 
smokers did not show fewer 
extrapyramidal side effects. 
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Examine the effect of recent 
tobacco and other 
substances use on 
psychiatric symptoms and 
quality of life outcomes and 
assess the illness severity 
and missed antipsychotic 
pills. 
51,4% Cigarette smoking was 
associated with higher ratings 
of psychiatric symptoms and 
functional impairment, more 
missed pills and lower ratings 



















Test: if substance use 
(including tobacco) 
following illness onset 
impairs medication 
adherence; if substance use 
is associated with poor 
outcome at 1 year follow-up 
and lastly if the poor 
medication adherence 









the 1 year 
follow-up 
evaluation. 
Nicotine dependence in the first 
year after psychosis onset 
affects medication adherence. 
Poor medication adherence 
predicts non-remission. 
Nicotine dependence in the first 
year after psychosis onset is 
associated with non-remission. 








Determine the prevalence 
and patterns of smoking and 
its co-use with cannabis in 
FEP and examine 
demographic, clinical, 
cognitive, and functional 
characteristics associated 
with smoking status, after 
adjusting for cannabis use. 
53,0% Neurocognitive and functional 
impairments are more 
prominent in light/moderate 
and heavy cigarette smokers 
with FEP relative to non-
smoking patients at initial 
presentation for treatment. 
(35) Australia 193 22,0 
(3,3) 




Clarify the impact of 
smoking on clinical 
outcomes 
72,0% There are not any impact of 
smoking on clinical outcomes 





The current systematic review provides convincing evidence that tobacco use have high 
rates in the first-episode psychosis, being in agreement, in fact, with the prior knowledge 
from previous studies (2). 
A meta-analysis of worldwide studies suggests that smoking begins before the first 
referral for treatment (37) and two prospective cohort studies indicated that smoking may 
begin before the onset of psychosis (38, 39). 
About this first topic “Tobacco smoking as a potential risk factor to first episode 
psychosis”, it was observed that, in spite of the percentage of patients who smoked for 
patients aged 20 years or more was superior than for teenage patients, suggesting that part 
of them started to smoke after the outset of the illness, in general, the mean age at starting 
smoke was significantly earlier than the functional decline and the onset of psychosis. In 
addition, smoker patients showed a nonsignificant better functioning compared to 
nonsmoker patients. Those patients who started smoking had better premorbid social 
functioning than those who did not smoke, which is contrary to what was expected in case 
smoking were initiated in response to early prodromal features of illness (26). These 
results make it possible to have a cause-effect relationship instead of tobacco smoking 
being just a consequence of first-episode psychosis, which is in line with the literature 
(37-39). 
Interestingly, Cannon and colleagues showed evidence for a relation between increased 
rate of conversion to psychosis and any substance use when entered in a prediction 
algorithm along with other predictors, although in multivariate analyses no specific 
substance class of the 7 tested (alcohol, hypnotics, cannabis, amphetamines, opiates, 
cocaine, and hallucinogens) (40). In this regard, it’s possible that the importance of 
substance use can be through its interactive effects with other substances, symptom 
severity or current level of functioning and therefore, the role of tobacco use for risk of 
conversion may be better tapped by multivariate prediction algorithms incorporating 
multiple variables implicated in psychosis onset. 
The cognitive approach to the self-medication hypothesis is supported by several studies 
(41-49). On the contrary, two studies found no significant differences in the general 
neurocognitive (non-social) functioning between nicotine user and non-user patients with 
psychosis (50, 51). In addition, regarding social cognition, one study published in 2013 
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did not find nicotine effects on social cognitive tasks (facial affect recognition) or on 
social competence (52), however the sample of schizophrenia patients in this study 
unexpectedly did not perform significantly worse in the facial affect recognition task than 
the healthy controls. Therefore, a precondition for showing performance-enhancing 
effects of nicotine in schizophrenia patients was not given, which may have contributed 
to the lack of nicotine effect on facial affect recognition. 
Regarding the second topic “Nicotine use in the form of tobacco smoking in first episode 
psychosis: the self-medication hypothesis”, the results of the current systematic review 
were, in an overall analysis, against the proposed hypothesis and the knowledge taken 
from previous studies. One study verified the association between severe dependence and 
lower severity of negative symptoms (28), supporting the self-medication hypothesis. On 
the other hand, one study included did not support the mentioned theory once no 
significant difference in cognitive ability has been found between smokers and non-
smokers (29) and another one concluded that tobacco smoking had no effect on 
psychopathology at initial presentation or treatment response at 6 weeks (30). Lastly, one 
of the included studies does not allow us to fully draw conclusions about this concern 
which shows that tobacco use in FEP patients is not related to better non-social or social 
cognitive performance, meanwhile, there was a lack of IQ matching between patients and 
healthy controls with the control group having higher IQ (27). So future longitudinal 
studies with healthy controls with a similar IQ and also measures of pre and post 
substance-use and FEP-onset cognitive function could overcome this limitation.  
Previously, published studies related to the association “Tobacco use as a marker of 
greater illness severity in first episode psychosis” are inconsistent.  
Some studies demonstrated that current smokers with schizophrenia exhibit greater 
working memory impairments than non-smokers (53) and worse cognitive and functional 
outcomes than past smokers or those who had never smoked (54). In addition, in a cohort 
of 542 inpatients with psychosis who were followed for 10 years after first hospitalization, 
smokers exhibited greater functional impairment than non-smokers, and depressive 
symptoms positively covaried with cigarette smoking over a 10-year period (55). And 
still, one study suggests that severe forms of schizophrenia with poor outcome were 
associated with heavy smoking (20).  
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Despite these findings, the clinical outcomes of patients who are chronically ill as the 
populations in the studies above mentioned may not be representative of the first-episode 
psychosis population. 
In this systematic review, as we have seen, this third topic was in line with the findings 
from chronically ill psychosis patients. The first study mentioned in this review on this 
topic, reached the conclusion that, although cognitive performance was better in patients 
with FEP who smoked than in non-smoking patients in selective attention and working 
memory soon after the first stabilization, in a different way, after 6 months initiation of 
antipsychotic treatment, baseline differences in selective attention and working memory 
parameters were no longer significant between smokers and non-smokers, with the 
exception of Stroop-I mean RT (Stroop Color-Word Test Interference score/Stroop-I, the 
measure of selective attention) and after 1 year, performance was similar between the 
groups (31). This could be explained once non-smokers might obtain more benefit from 
practice effects, since they start with a more disadvantageous performance than smokers, 
as various studies have pointed out that worse baseline scores predict greater cognitive 
improvement (56, 57). Another explanation for the improvements in non-smokers might 
be through the therapeutic effects of SGA on cognition. Olanzapine and risperidone, for 
example, have been reported to provide a modest cognitive improvement during the early 
phase (58), so this may have led non-smokers to achieve the superior baseline cognitive 
performance of smokers, which was probably obtained through nicotinic stimulation. In 
this case, once nicotine use leads to a cognitive benefit also achievable from antipsychotic 
medication during the early course of the illness (6–12 months), it could be a support for 
the self-medication hypothesis. In addition, once smokers seem to have difficult to benefit 
from practice effects from medication, it gives strength to the hypothesis that smoking 
may be a marker of more severe illness. Another point that deserves attention is that 
smokers did not show any cognitive response to SGA, with no synergic effects observed 
for nicotine and antipsychotics. Explanations for the lack of an additional cognitive 
benefit in smokers promoted by the SGA, can be a possible ceiling effect of the agonist 
activity that may be obtained through smoking and/or SGA or the possibility of an 
etiologically differentiated system with more marked alterations among smokers, which 
might prevent smokers from benefitting from practice effects, suggesting that smoking 
may be a marker of more severe illness and/or of its neurodevelopmental phenotype, as 
it was suggested by some authors (15, 20). Also supporting this hypothesis, although the 
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results of this study indicate that the initial clinical presentation is the same between 
groups, it was found that negative symptoms worsen significantly in smokers (31). With 
respect to the exploration of the association between smoking and symptoms and side 
effects of medication, this study results do not support that FEP patients smoke in order 
to reduce the side effects of antipsychotic drugs, once smokers did not show fewer 
extrapyramidal side effects comparative to non-smokers (31). The second one study 
mentioned, documented that cigarette smoking was consistently associated with higher 
ratings of psychiatric symptoms and functional impairment, more missed pills and lower 
ratings of quality of life (32), also encouraging the hypothesis of tobacco being a marker 
of greater illness severity. In other study included in this systematic review (33), the 
results also agree with the assumption, showing that in fact nicotine dependence in the 
first year after psychosis onset affects medication adherence, poor medication adherence 
predicts non-remission and lastly nicotine dependence in the first year after psychosis 
onset is associated with increased probability of non-remission during the one year 
follow-up suggesting a role to poor medication adherence in this as a causal pathway by 
mediating this connection. This study evaluated the impact of substance use, both 
premorbid and after psychosis onset, on medication adherence and the conclusion was 
that premorbid substance use does not affect medication adherence during the one year 
follow-up but its use during the year after psychosis onset predicted poor medication 
adherence at follow-up. Moreover, one study showed that substance use increases the risk 
of non-remission, with a more than 2-fold increased likelihood of not achieving remission 
in the case of nicotine dependent patients (59). These results make emerge a new possible 
explanation for the association between tobacco use and worst outcomes at follow-up 
which is poor medication adherence as a causal pathway by mediating this connection. In 
the study of Grossman and colleagues (34), it was observed that neurocognitive and 
functional impairments are more prominent in light/moderate and heavy cigarette 
smokers with FEP relative to non-smoking patients at initial presentation for treatment, 
also reinforcing this theory. The last one was the only which disapproved the hypothesis 
once after adjustment for cofounders, the conclusion was that there are not any impact of 
smoking on clinical outcomes in individuals after a first episode psychosis (35). One 
possible explanation for this disagreement is that the first episode psychosis study 
population that participated in this study may not be a real representative of this 




As it has been analyzed, the evidence supporting the existence of an association between 
tobacco use and first episode psychosis patients is undeniable. The discrepancy in the 
nature of this association mainly in relation to the first two hypothesis “Tobacco smoking 
as a potential risk factor to first episode psychosis” and “Nicotine use in the form of 
tobacco smoking in first episode psychosis: the self-medication hypothesis” makes it 
difficult to clearly understand which hypothesis contributes more to the aforementioned 
relationship, although, according to this meta-analysis, a trend towards a greater 
contribution of the first proposed hypothesis. The third topic “Tobacco use as a marker 
of greater illness severity in first episode psychosis” seems to be the one with the greatest 
confidence. One of the studies included makes emerge a new possible explanation for the 
association between tobacco use and worst outcomes at follow-up which is poor 
medication adherence as a causal pathway by mediating this connection. It is clear that 
more studies will be needed to overcome some of the limitations of the previous studies 
that have been mentioned; however, the conclusion of this meta-analysis, if duly proven, 
may be very useful in clinical practice, primarily in a view of prevention through anti-
smoking measures in risk groups and also tobacco use may be used as an accessory 
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Resumo Extenso em Português 
O primeiro episódio psicótico define-se como uma síndrome variável, com duração 
mínima de uma semana e que se caracteriza pela presença de sintomas positivos, 
predominantemente alucinações e delírios, e outros sintomas acompanhantes que incluem 
os negativos, os afetivos e o abuso de substâncias. Tipicamente, apresenta o seu início na 
adolescência ou no início da idade adulta. 
A prevalência do uso do tabaco em doentes com primeiro episódio psicótico é 
marcadamente alta, cerca de 59%, sendo superior à da população em geral. 
Têm sido propostas diversas teorias com o objetivo de explicar a razão pela qual os 
doentes com primeiro episódio psicótico apresentam uma maior predisposição para 
iniciar e manter o uso do tabaco. 
Foi sugerida a existência de uma relação de causa-efeito do tabaco em relação à doença, 
tendo em conta resultados observados na associação entre o uso do tabaco e um risco 
aumentado de psicose. 
Por outro lado, também emergiu a questão de que a alta prevalência de tabagismo neste 
grupo de doentes poderia ser justificada como uma tentativa de auto-medicação (the self-
medication behaviour). 
Foi ainda sugerido que o uso do tabaco poderia servir como marcador de uma maior 
gravidade da doença psicótica, tendo em conta que o tabagismo foi associado a um 
aumento dos sintomas negativos e positivos, assim como a uma pior função global e 
capacidades sociais. No entanto, isto poderá não ser representativo da população referente 
ao primeiro episódio psicótico, uma vez que os resultados clínicos provém de doentes 
com doença psicótica crónica. 
Esta revisão sistemática reuniu os estudos publicados até ao março de 2018, através da 
pesquisa nas bases de dados Pubmed e Web of Knowledge, sobre a relação referida de 
forma a estudar três tópicos principais que poderão contribuir para a associação entre o 
tabaco e o primeiro episódio psicótico: Tabaco como fator de risco do primeiro episódio 
psicótico; A exposição à nicotina, através do tabaco, como comportamento de auto-
medicação; e Tabaco como marcador de maior gravidade da doença. Foram incluídos dez 
artigos originais, dos quais: um estudou o primeiro tópico acima referido; quatro 




No total, foram incluídos 2567 doentes, com um tamanho de amostra que variou entre 41 
a 503 doentes, com média de idade entre 20,5 e 29,9 anos, com percentagem de sexo 
masculino entre 28,1 e 72,5%. Dois dos estudos são provenientes do Canadá, quatro de 
Espanha, um do Reino Unido, um da Austrália, um dos Estados Unidos da América e um 
da Polónia. Três dos estudos foram publicados entre 2008 e 2012 e sete entre 2015 e 2018. 
Em relação à prevalência do tabagismo nos doentes com primeiro episódio nos artigos 
incluídos nesta revisão sistemática, esta variou entre 36,7% e 72,0%, sendo que em um 
dos artigos não foi possível determinar a mesma. 
Os resultados acerca do primeiro tópico “Tabaco como fator de risco do primeiro episódio 
psicótico” apoiaram a hipótese. Mais especificamente, o artigo incluído mostrou que, 
apesar da percentagem de doentes fumadores com idade superior ou igual a 20 anos ser 
superior à percentagem de doentes fumadores com idade inferior, sugerindo, neste caso, 
que parte dos doentes começaram a fumar apenas após o início da doença, por outro lado, 
no geral, a média de idade de início do tabagismo foi significativamente inferior ao 
declínio funcional e início do primeiro episódio psicótico. Além disto, no mesmo artigo 
os doentes fumadores apresentaram um melhor desempenho funcional não significativo 
comparativamente aos doentes não fumadores e ainda aqueles doentes que começaram a 
fumar mostraram ter melhores resultados nas capacidades sociais a nível prémorbido em 
relação aos doentes que não fumaram, o que contraria o que seria expectável no caso do 
tabagismo ser iniciado como resposta aos sintomas iniciais da doença. Estes resultados 
tornam possível a existência de uma relação causa-efeito e não apenas o uso do tabaco 
como consequência da manifestação da doença.  
Acerca do tópico “A exposição à nicotina, através do tabaco, como comportamento de 
auto-medicação”, os quatro artigos incluídos obtiveram resultados divergentes com um 
resultado geral que não apoia a hipótese sugerida. Um dos estudos verificou a associação 
entre a dependência severa à nicotina e uma redução da severidade dos sintomas 
negativos, suportando a hipótese sugerida. Por outro lado, um dos estudos não apoiou a 
mesma, uma vez que não foram observadas diferenças nas funções cognitivas entre  
doentes fumadores e não fumadores e, ainda, mais um dos estudos incluídos, concluíu 
que o tabaco não tinha qualquer efeito na psicopatologia nem na apresentação inicial da 
doença nem na resposta ao tratamento às 6 semanas. Por último, um dos estudos não 
permitiu totalmente extrapolar conclusões uma vez que o tabagismo nos doentes incluídos 
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não se relacionou com melhores resultados nas funções cognitivas, no entanto, o estudo 
referido apresenta uma falta de concordância relativamente ao QI entre o grupo dos 
doentes e o grupo controlo, com o último a apresentar um valor de QI superior.  
Em relação ao último tópico “Tabaco como marcador de maior gravidade da doença”, 
quatro dos cinco artigos incluídos suportam a hipótese. Num dos artigos referidos, os 
doentes fumadores, após 6 meses e 1 ano de seguimento, perderam a superioridade que 
apresentavam anteriormente relativa às funções cognitivas, os sintomas negativos 
agravaram-se de forma mais marcada nos doentes fumadores e estes não mostraram 
apresentar diminuição dos efeitos extra-piramidais, sugerindo que o uso do tabaco não é 
iniciado ou mantido de forma a diminuir os efeitos adversos dos fármacos anti-psicóticos. 
Num segundo estudo referido, o tabaco mostrou estar associado a taxas superiores de 
sintomas psicóticos e a um maior compromisso funcional. No terceiro estudo, foi 
concluído que: a dependência à nicotina um ano após o primeiro episódio psicótico 
diminui a adesão à terapêutica; a fraca adesão à terapêutica prediz a não remissão da 
doença; e a dependência à nicotina um ano após o primeiro episódio psicótico está 
associado à não remissão da doença. Sugere-se assim que a adesão à terapêutica apresenta 
um papel de mediador da relação entre o tabaco e um maior grau de gravidade do primeiro 
episódio psicótico. Ainda, um dos artigos incluídos mostrou que o comprometimento a 
nível neurocognitivo e funcional é mais proeminente em doentes fumadores em relação 
aos não fumadores na apresentação inicial da doença. Por último, apenas um dos artigos, 
não apoiou a hipótese, tendo em conta que mostrou não existir qualquer impacto do tabaco 
nos resultados clínicos dos doentes após o primeiro episódio psicótico. 
Como foi analisado, existe bastante evidencia que suporta a associação entre o tabagismo 
e o primeiro episódio psicótico. No entanto, a discrepância observada nos resultados, 
principalmente em relação aos tópicos “Tabaco como fator de risco do primeiro episódio 
psicótico” e “A exposição à nicotina, através do tabaco, como comportamento de auto-
medicação” dificulta a compreensão da verdadeira natureza desta relação, apesar de, 
segundo esta meta-análise, haver uma tendência para uma maior contribuição da primeira 
hipótese na génese da mesma. Em relação à hipótese “Tabaco como marcador de maior 
gravidade da doença”, esta foi aquela que mais foi corroborada, com a quase totalidade 
dos estudos incluídos a suportar esta hipótese. 
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Deste modo, no caso de as hipóteses “Tabaco como fator de risco do primeiro episódio 
psicótico” e “Tabaco como marcador de maior gravidade da doença” serem totalmente 
provadas estas poderão ter uma utilidade clínica muito vantajosa. No caso da primeira 
hipótese, numa perspetiva de prevenção através de medidas anti-tabágicas nos grupos de 
risco; na segunda, a utilização do uso do tabaco como marcador do estadiamento do 
primeiro episódio psicótico, inclusivamente com um provável valor prognóstico 
associado. 
 
 
 
